103 related articles for article (PubMed ID: 2541144)
1. Cytotoxicity mediated by tumor necrosis factor in variant subclones of the ME-180 cervical carcinoma line: modulation by specific inhibitors of DNA topoisomerase II.
Coffman FD; Green LM; Godwin A; Ware CF
J Cell Biochem; 1989 Feb; 39(2):95-105. PubMed ID: 2541144
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.
Baloch Z; Cohen S; Coffman FD
J Immunol; 1990 Nov; 145(9):2908-13. PubMed ID: 2170526
[TBL] [Abstract][Full Text] [Related]
3. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
4. The relationship of receptor occupancy to the kinetics of cell death mediated by tumor necrosis factor.
Coffman FD; Green LM; Ware CF
Lymphokine Res; 1988; 7(4):371-83. PubMed ID: 2850412
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Utsugi T; Mattern MR; Mirabelli CK; Hanna N
Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
7. Positive and negative selection for tumor necrosis factor responsiveness reveals an inhibitory role for EGF receptor in TNF-induced antiproliferation.
Nishikawa K; Rotbein J; Vijjeswarapu D; Owen-Schaub L; Rosenblum MG; Donato NJ
Lymphokine Cytokine Res; 1994 Feb; 13(1):37-45. PubMed ID: 8186323
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells.
Donato NJ; Yan DH; Hung MC; Rosenblum MG
Cell Growth Differ; 1993 May; 4(5):411-9. PubMed ID: 8518234
[TBL] [Abstract][Full Text] [Related]
9. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II.
Alexander RB; Nelson WG; Coffey DS
Cancer Res; 1987 May; 47(9):2403-6. PubMed ID: 2436763
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
11. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines.
Morimoto H; Safrit JT; Bonavida B
J Immunol; 1991 Oct; 147(8):2609-16. PubMed ID: 1918981
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.
Utsugi T; Demuth S; Hanna N
Cancer Res; 1989 Mar; 49(6):1429-33. PubMed ID: 2538225
[TBL] [Abstract][Full Text] [Related]
14. Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines.
Browning J; Ribolini A
J Immunol; 1989 Sep; 143(6):1859-67. PubMed ID: 2550545
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
Wolverton JS; Danks MK; Granzen B; Beck WT
Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
[TBL] [Abstract][Full Text] [Related]
17. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
18. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
Kerrigan D; Pommier Y; Kohn KW
NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of human glioblastoma T98G cells to VP16 and VM26 by human tumor necrosis factor.
Morgavi P; Cimoli G; Ottoboni C; Michelotti A; Conte P; Parodi S; Russo P
Anticancer Res; 1995; 15(4):1423-8. PubMed ID: 7654031
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
